Comparison · NCT00004031-sae
CHOP/CHOP-R x 3 vs CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. CHOP/CHOP-R x 3 vs CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant: serious adverse events. Trial comparisons, record NCT00004031-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00004031-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0325 | 0.0127 | 0.0806 | wilson | |
| Risk in group 2 | 0.0354 | 0.0139 | 0.0875 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00288 | -0.0586 | 0.0498 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.919 | 0.235 | 3.59 | log | |
| Odds ratio, group 1 over group 2 | 0.916 | 0.224 | 3.75 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on CHOP/CHOP-R x 3 than on CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | 347 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | CHOP/CHOP-R x 3 | Cyclophosphamide 750 mg/m2 IV Day 1 Doxorubicin 50 mg/m2 IV Day 1 Prednisone 100 mg/day PO Days 1-5 Vincristine 1.4 mg/m2 IV Day 1 Rituximab 375 mg/m2 IV Day 1 This regimen is repeated every 21 days for 8 cyclesXXrituximab: 375 mg/m2 IV every 21 daysXXCHOP regimenXXcyclophosphamideXXdoxorubicin hydrochlorideXXprednisoneXXvincristine sulfateXXbone marrow ablation with stem cell support | 4 | 123 | EG000 |
| Group 2 | CHOP/CHOP-R x 1 + Autologous Stem Cell Transplant | Cyclophosphamide 750 mg/m2 IV Day 1 Doxorubicin 50 mg/m2 IV Day 1 Prednisone 100 mg/day PO Days 1-5 Vincristine 1.4 mg/m2 IV Day 1 Rituximab 375 mg/m2 IV Day 1 This regimen is repeated every 21 days for 6 cycles followed by autologous stem cell transplant.XXrituximab: 375 mg/m2 IV every 21 daysXXCHOP regimenXXcarmustineXXcyclophosphamideXXdoxorubicin hydrochlorideXXetoposideXXprednisoneXXvincristine sulfateXXbone marrow ablation with stem cell supportXXperipheral blood stem cell transplantationXXradiation therapy | 4 | 113 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Duration of treatment and follow up until death or 3 years post registration
Source ClinicalTrials.gov
Trial
- Title
- SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
- NCT number
- NCT00004031
- Phases
- PHASE3
- Conditions
- Lymphoma
- Interventions
rituximab, CHOP regimen, carmustine, cyclophosphamide, doxorubicin hydrochloride, etoposide, prednisone, vincristine sulfate, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation, radiation therapy
- Lead sponsor
- SWOG Cancer Research Network
- Results first posted
- 2021-02-02
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00004031?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00004031-sae